Ublituximab for the treatment of CD20 positive B-cell malignancies

Hani M. Babiker, Ashley E. Glode, Laurence S. Cooke, Daruka Mahadevan

Producción científica: Articlerevisión exhaustiva

37 Citas (Scopus)


Introduction: Non-Hodgkin lymphoma (NHL) is the most common adult hematologic malignancy. Conventional methods of treatment are chemotherapy and radiation, which were associated with toxicities and lack of specificity. Potential cell surface targets for treatment of B-cell NHL (B-NHL) include CD19, CD20, and CD22 which are highly expressed on malignant B-cells. The development of monoclonal antibody (mAb) therapy directed against CD20 had the most clinical impact in the treatment of B-NHL. Early clinical trials with rituximab (RTX), the first chimeric mAb against CD20, showed efficacy and minimal toxicities. RTX was later approved as first line in combination with CHOP chemotherapy for Diffuse Large B-NHL (DLBCL). The emergence of resistance to RTX prompted the development of the next-generation of mAbs targeting CD20 (e.g. obinituzumab, ofatumumab), and includes ublituximab (Ub), with higher complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against malignant B-cells. Areas covered: Herein, we discuss clinical trials of Ub, highlighting efficacy, tolerability and an expert opinion on drug development in B-NHL. A pubmed search was conducted to evaluate all Ub clinical trials. Expert opinion: Ub demonstrated efficacy in patients with high-risk CLL and B-NHL in both first line, subsequent lines, and in rituximab refractory patients.

Idioma originalEnglish (US)
Páginas (desde-hasta)407-412
Número de páginas6
PublicaciónExpert Opinion on Investigational Drugs
EstadoPublished - abr 3 2018
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Profundice en los temas de investigación de 'Ublituximab for the treatment of CD20 positive B-cell malignancies'. En conjunto forman una huella única.

Citar esto